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Synergistic functions of E2F7 and E2F8 are critical to
suppress stress-induced skin cancer
I Thurlings1,5, LM Martínez-López1,5, B Westendorp1,5, M Zijp1, R Kuiper1,6, P Tooten1, LN Kent2, G Leone2, HJ Vos3, B Burgering3
and A de Bruin1,4
E2F transcription factors are important regulators of the cell cycle, and unrestrained activation of E2F-dependent transcription is
considered to be an important driver of tumor formation and progression. Although highly expressed in normal skin and skin
cancer, the role of the atypical E2Fs, E2F7 and E2F8, in keratinocyte homeostasis, regeneration and tumorigenesis is unknown.
Surprisingly, keratinocyte-speciﬁc deletion of E2F7 and E2F8 in mice did not interfere with skin development and wound healing.
However, the rate for successful isolation and establishment of E2f7/8-deﬁcient primary keratinocyte cultures was much higher than
for wild-type keratinocytes. Moreover, E2f7/8-deﬁcient primary keratinocytes proliferate more efﬁciently under stress conditions,
such as low/high conﬂuence or DNA damage. Application of in vivo stress using the DMBA/TPA skin carcinogenesis protocol
revealed that combined inactivation of E2f7/8 enhanced tumorigenesis and accelerated malignant progression. Loss of atypical
E2Fs resulted in increased expression of E2F target genes, including E2f1. Additional loss of E2f1 did not rescue, but worsened skin
tumorigenesis. We show that loss of E2F7/8 triggers apoptosis via induction of E2F1 in response to stress, indicating that the tumor-
promoting effect of E2F7/8 inactivation can be partially compensated via E2F1-dependent apoptosis. Importantly, E2F7/8 repressed
a large set of E2F target genes that are highly expressed in human patients with skin cancer. Together, our studies demonstrate
that atypical E2Fs act as tumor suppressors, most likely via transcriptional repression of cell cycle genes in response to stress.
Oncogene (2017) 36, 829–839; doi:10.1038/onc.2016.251; published online 25 July 2016
INTRODUCTION
Disruption of pathways controlling E2F activity is considered a
critical event of tumorigenesis.1 Transcriptional activation of
cell cycle genes by E2Fs is inhibited through direct interaction
with the retinoblastoma protein (RB).2 Importantly, most human
cancers show alterations in the upstream regulators of RB, such as
cyclins, or carry RB mutations resulting in disruption of RB/E2F
interaction and consequently the upregulation of E2F-dependent
transcription.3
Recent studies demonstrated that expression of E2F target
genes is induced by transcriptional activator E2Fs, and counter-
balanced by transcriptional repressors E2F7 and E2F8 during
S- and G2-phase.1,4,5 In addition to their role to control this
downswing of oscillating cell cycle genes, there is evidence that
E2F7/8 are also involved in the transcriptional repression of cell
cycle genes during DNA damage.6,7 E2F7 and E2F8 expression is
induced in response to DNA damage, which is partially dependent
on P53.6–8 The exact function of E2F7/8 during DNA damage is
unclear, but transcriptional inhibition of cell cycle progression to
enable optimal DNA repair is likely, as high E2F7/8 levels inhibit
proliferation in vitro.4,9–14
There is evidence that E2F7/8 have a particularly important role
in the maintenance of the squamous epithelium of the skin.
In vitro experiments suggested that E2F7 downregulation drives
squamous differentiation.15 Furthermore, E2F7 levels in squamous
carcinoma cell lines affected proliferation and sensitivity to the
chemotherapeutic drug doxorubicin.16 In vivo studies on the
function of E2F7 and E2F8 in skin are currently lacking. We show
here that E2F7/8 are dispensable for normal skin function and
wound healing, but deletion leads to increased numbers of skin
tumors and enhanced malignant progression in a two-stage skin
carcinogenesis model. E2F7/8-deﬁcient keratinocytes displayed
increased expression of E2F1 and enhanced apoptosis during
tumor initiation. Loss of E2F1 reduced apoptosis and accelerated
tumorigenesis in E2F7/8-deﬁcient tumors. These ﬁndings suggest
that E2F1-induced apoptosis might partially compensate for
the loss of the tumor suppressor functions of E2F7/8.
RESULTS
Atypical E2F function is not required for skin development,
maintenance and regeneration
Our previous studies demonstrated that synergistic functions
of atypical E2Fs are essential for placental development and
embryonic survival in mice.17,18 To investigate the role in adult
tissues, we conditionally ablated E2F7 and E2F8 in the skin.9,14 We
crossed E2f7LoxP/LoxP;E2f8LoxP/LoxP mice (from here on referred to as
control) with transgenic K14-Cre mice. We conﬁrmed keratinocyte-
speciﬁc Cre activity by interbreeding the K14-Cre;E2f7Δ/Δ;E2f8Δ/Δ
mice (from here on referred to as E2f7Δ/ΔE2f8Δ/Δ mice) with
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Cre-reporter mice (R26R-LacZLoxP/LoxP). LacZ expression was
detected in keratinocytes of adult K14-Cre;E27Δ/Δ;E2f8Δ/Δ;R26RΔ/Δ
mice (Figure 1a).
Mice with keratinocyte-speciﬁc combined deletion of E2f7 and
E2f8, as well as mice with conventional single deletion of E2f7 or
E2f8 were monitored until old age. Survival between these ageing
cohorts did not differ and histopathological analysis of the
skin revealed no signiﬁcant microscopic lesions compared with
age-matched control littermates (Figure 1b, data not shown).
Wound-healing assays revealed that combined loss of E2f7 and
E2f8 did not perturb skin regeneration in vivo (Figure 1c).
Together, these data suggest that atypical E2Fs are not required
for skin development, maintenance and regeneration in mice.
These ﬁndings are surprising, because previous in vitro studies
indicated that E2F7 can regulate proliferation and survival in
human primary keratinocytes.19 We therefore isolated primary
keratinocytes from our mice to determine whether inactivation of
atypical E2Fs had any impact on proliferation or apoptosis under
in vitro conditions. We conﬁrmed absence of targeted mRNA and
proteins in extracts from primary keratinocytes (Supplementary
Figure 1). Interestingly, we observed that the success rate for
establishment of primary keratinocyte cultures was higher for
E2f7Δ/ΔE2f8Δ/Δ keratinocytes than for control keratinocytes
(Figure 2a). These observations suggest that E2f7Δ/ΔE2f8Δ/Δ
keratinocytes might have a growth advantage under severe stress
conditions. Next, we cultured keratinocytes under low- and high-
conﬂuence conditions and found that E2f7Δ/ΔE2f8Δ/Δ keratinocytes
reached higher cell counts than control keratinocytes (Figure 2b).
Our previous studies demonstrated that E2F1 is a key
transcriptional target of the atypical E2Fs and inactivation of
E2F1 rescued multiple phenotypes induced by inactivation
of E2F7/8.18,20 To explore whether E2F1 contributes to enhanced
growth performance of E2f7Δ/ΔE2f8Δ/Δ keratinocytes, we generated
K14-Cre-E2f7Δ/ΔE2f8Δ/Δ;E2f1−/− mice and isolated primary
keratinocytes with triple deletions. The isolation and successful
establishment of primary E2f7Δ/ΔE2f8Δ/ΔE2f1−/− cultures occurred
at similar efﬁciency as for E2f7Δ/ΔE2f8Δ/Δ cultures (Figure 2a).
Surprisingly, E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes reached higher
cell counts than E2f7Δ/ΔE2f8Δ/Δ under low conﬂuence and similar
cell counts under high-conﬂuence conditions (Figure 2b). These
ﬁndings suggest that increased expression of E2F1 in E2f7Δ/ΔE2f8Δ/Δ
keratinocytes does not contribute to increased proliferation rate,
but instead has an inhibitory effect on cell growth performance of
E2f7Δ/ΔE2f8Δ/Δkeratinocytes. We failed to isolate keratinocytes
from E2f1−/−mice, which is in line with previous studies describing
that reduced levels of E2F1 can lead to growth arrest in
keratinocytes.21 Interestingly, this inability to isolate and culture
E2f1−/− keratinocytes can be rescued by inactivation of atypical
E2Fs, providing further support that loss of E2F7/8 makes
keratinocytes more resistant against stress signals that inhibit
proliferation.
E2F7/8 inhibit DNA replication during DNA damage in primary
keratinocytes
We next exposed our primary keratinocytes to DNA damage
agents, as previous studies suggest that E2F7/8 have a role in the
DNA damage response.6–8,22 However, these previous studies
were performed in transformed human cancer cell lines, in which
the physiological DNA damage response might already be altered.
Furthermore, mechanisms how E2F7/8 participate in the DNA
damage response are still unclear. We treated keratinocytes
with etoposide, a topoisomerase II inhibitor that causes single-
and double-strand DNA breaks, to induce DNA damage.23 DNA
damage was quantiﬁed at single-cell level by performing
phosphorylated γH2Ax immunoﬂuorescence staining and analyz-
ing the ﬂuorescence intensity per keratinocyte nucleus. Eight
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Figure 1. Keratin-14-Cre expression leads to speciﬁc deletion of genes in epidermis. (a) Microscopic pictures of normal skin of mice with
indicated genotypes, stained with X-Gal. (b) Mice were followed to old age for survival analysis (control n= 5; 78Δ/Δ n= 12). Differences are not
statistically signiﬁcant, log-rank, Mantel–Cox test. (c) A full-thickness biopsy wound was induced on the dorsal midline of mice (n= 3 per
genotype). The height and width of the wound were measured and the wound area is described as the percentage relative to the wound area
on day 1 after injury.
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γH2Ax levels in keratinocytes of all three genotypes (Figure 3a).
The mean intensity for γH2Ax staining between the three
genotypes did not differ signiﬁcantly, indicating that deletion of
atypical E2Fs with or without E2F1 in murine keratinocytes had no
major effect on DNA damage. Interestingly, E2f7Δ/ΔE2f8Δ/ΔE2f1−/−
keratinocytes exposed to DNA damage agents displayed a larger
cell-to-cell variability of γH2Ax phosphorylation, where some cells
displayed exceptional high levels and other cells showed very low
levels (Figure 3a, Supplementary ﬁgure 2). This observation
suggests that a subpopulation of E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratino-
cytes might have more DNA damage, which is in line with
previous studies suggesting that E2F1 promotes DNA repair24,25 or
that E2F1 is required for inducing apoptosis in cells exhibiting
high levels of DNA damage.1 Interestingly, the appearance of
E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes with reduced DNA damage
might suggest that E2F1 deﬁciency could also promote DNA
repair in a certain subpopulation, however the mechanism is
unclear.
A critical response to DNA damage is the induction of a cell
cycle arrest through blocking DNA replication. Strikingly, analysis
of BrdU incorporation revealed that neither E2f7Δ/ΔE2f8Δ/Δ nor
E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes showed a reduction in DNA
synthesis after etoposide treatment, whereas control cells showed
a profound reduction in BrdU incorporation in response to
etoposide (Figure 3b). These ﬁndings suggest that E2F7/8 are
essential for the induction of an S-phase arrest in response to DNA
damage.
We then investigated whether double- and triple-knockout
keratinocytes could enter mitosis under DNA damaging conditions
by evaluating phospho-Ser10-histone H3 (pH3) immunoﬂuores-
cence staining. Notably, etoposide treatment reduced the number
of pH3-positive control cells markedly, while E2f7Δ/ΔE2f8Δ/Δ and
E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes showed only partly reduced
numbers of pH3-positive cells (Figure 3c). Close inspection
revealed that pH3-positive double- and triple-knockout cells in
presence of etoposide exclusively showed a dotted pattern,
indicating that these cells are in late G2-phase. No pan-nuclear
pH3 staining or mitotic ﬁgures were seen in etoposide-treated
E2f7Δ/ΔE2f8Δ/Δ and E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes (Figure 3c).
However, we detect mitotic ﬁgures in E2f7Δ/ΔE2f8Δ/ΔE2f1−/−
keratinocytes when we reduced the dose of etoposide to 5 μM,
and in E2f7Δ/ΔE2f8Δ/Δ and E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes
when the concentration of etoposide was further reduced to
1 μM, while the control keratinocytes still show no (5 μM), or highly
reduced (1 μM) mitotic staining (Figure 3d).
Next, we performed gene expression analysis to further
evaluate the DNA damage response in keratinocytes. Western
blot analysis showed strongly induced protein levels of P53 and its
transcriptional target P21Cip1 after etoposide treatment, in a
comparable manner between control, E2f7Δ/ΔE2f8Δ/Δ and E2f7Δ/Δ
E2f8Δ/ΔE2f1−/− keratinocytes (Figure 3e), suggesting that the p53-
p21 axis in response to DNA damage is intact in these cells.
Interestingly, etoposide treatment reduced Cyclin B1 protein in
control, but not in E2f7Δ/ΔE2f8Δ/Δ and E2f7Δ/ΔE2f8Δ/ΔE2f1−/−
keratinocytes (Figure 3e). This accumulation of Cyclin B1 in
etoposide-treated double- and triple-knockout keratinocytes
occurred independently of transcriptional regulation (Figure 3f),
and is consistent with the pH3 data suggesting an accumulation
of mutant keratinocytes in late G2-phase under DNA damaging
conditions.
As E2F7 and E2F8 repress many genes relevant for entry and
progression of DNA replication, we investigated the expression of
E2F target genes in untreated and etoposide treated keratino-
cytes. The protein levels of the E2F target CDC6, an essential factor
for DNA replication initiation, were markedly induced by loss of
E2f7/8. Remarkably, additional E2f1 deletion, which is known to
trans-activate Cdc6, did not rescue this induction. Etoposide
treatment reduced the protein levels of CDC6 in control as well as
double knockout and triple knockout keratinocytes (Figure 3e).
However, protein levels of CDC6 in etoposide-treated E2f7Δ/ΔE2f8Δ/Δ
and E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes were still similar to
untreated control cells, consistent with a failure of double- and
triple-knockout keratinocytes to block DNA synthesis during DNA
damage. Transcript levels of Mcm2, another E2F target gene
involved in DNA replication, showed a similar induction by loss of
E2F7 and E2F8 as Cdc6 under both untreated and DNA damaging
conditions (Figure 3g). Together, these data indicate that E2F7 and
E2F8 are required to arrest primary keratinocytes in S-phase
during DNA damage.
Loss of E2f1 inhibits apoptosis in E2f7Δ/ΔE2f8Δ/Δ keratinocytes
during in vitro and in vivo stress
Given that E2f7Δ/ΔE2f8Δ/ΔE2f1−/− keratinocytes reached higher cell
numbers under low-conﬂuence conditions than E2f7Δ/ΔE2f8Δ/Δ
keratinocytes (Figure 2b), we investigated whether E2F1 promotes
apoptosis in E2f7Δ/ΔE2f8Δ/Δ keratinocytes upon stress, such as
exposure to different DNA damaging agents. qPCR and western
blot analysis revealed that E2f1 RNA and protein levels were
increased in keratinocytes lacking E2F7/8 (Supplementary
Figure 1). We induced DNA damage in primary keratinocytes with
either etoposide or camptothecin, and measured numbers of
Annexin-V+ cells by FACS analysis (Figures 4a and b). Etoposide
and camptothecin caused a mild increase in apoptosis in control







































































Figure 2. Isolation and culture of E2f7/E2f8 mutant keratinocytes. (a) Isolation success rate of primary mouse keratinocyte cultures (control,
78Δ/Δ and 78Δ/Δ1−/− n= 8; 1−/− n= 2). (b) Quantiﬁcation of cell growth under low and high conﬂuence. Cells were cultured for 8 days and
counted (n= 3 per genotype). (a and b) *Po0.05 vs control.
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E2f8Δ/Δ keratinocytes, in particular after camptothecin treatment.
In contrast, the number of apoptotic cells was lower in E2f7Δ/Δ
E2f8Δ/ΔE2f1−/− keratinocytes compared with E2f7Δ/ΔE2f8Δ/Δ kerati-
nocytes, suggesting that E2F1 induces apoptosis in stressed
keratinocytes lacking atypical E2Fs. To complement these ﬁndings
by in vivo studies, we stressed the skin of control, E2f7Δ/ΔE2f8Δ/Δ
and E2f7Δ/ΔE2f8Δ/ΔE2f1−/− mice with a single application of 7,12-
dimethylbenz[a]anthracene (DMBA), which leads to the formation
of DNA adducts. Skin samples were harvested after 24 h to
measure the numbers of apoptotic (TUNEL-positive) cells per mm
of epidermis. Notably, E2f7Δ/ΔE2f8Δ/Δ mice showed higher
numbers of apoptotic cells compared with control littermates.
control 78∆/∆ 78∆/∆1-/-
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Importantly, in E2f7Δ/ΔE2f8Δ/ΔE2f1−/− mice this increase of apopto-
tic cells was reduced (Figure 4c, P= 0.06). Collectively, we show
that E2F1 mediates an enhanced apoptotic response to DNA
damage in E2f7Δ/ΔE2f8Δ/Δ keratinocytes.
Synergistic functions of E2F7 and E2F8 are critical for tumor
suppression in the skin
Next, we determined whether atypical E2Fs contribute to long-
term stress responses in vivo by performing a two-stage skin
carcinogenesis study using DMBA and 12-O-tetradecanoyl-phor-
bol-13-acetate (TPA). Adult mice were exposed to a single dose of
DMBA (tumor initiation), followed by TPA treatments twice a week
(tumor promotion) for 15 weeks (Figure 5a). Strikingly, the
combined deletion of E2f7/8 caused a signiﬁcant increase in the
number of tumors per mouse over the course of TPA treatment
(Figure 5b). Moreover, tumors in E2f7Δ/ΔE2f8Δ/Δ mice grew
signiﬁcantly faster than control tumors (Figures 5c and d). We
conﬁrmed that K14-cre-mediated deletion occurred in the
keratinocytes of skin tumors (Supplementary Figure 3). A board-
certiﬁed veterinary pathologist analyzed histology sections of
tumors to evaluate malignant progression, and these were
categorized into papilloma, carcinoma in situ, or squamous cell
carcinoma (SCC) 1-3, where SCC-3 represents the most advanced
stage (Figures 5e and f). During 15 weeks of TPA treatment, none
of the control tumors reached the SCC-2 or SCC-3 stages (invasion
into dermis and subcutaneous muscle, respectively), whereas
almost 20% of the E2f7Δ/ΔE2f8Δ/Δ tumors did (Figure 5e). The
tumor-suppressing effects of E2F7 and E2F8 are redundant,
because mice with single conventional deletions of E2f7 or E2f8
did not show enhanced tumor formation or malignant progres-
sion compared with their control littermates (Supplementary
Figure 4). In some in vivo mouse models, Cre activity can cause
DNA damage and genetic instability.26,27 Therefore, we conﬁrmed
that Cre expression on its own did not increase tumor formation
and progression. K14-Cre mice displayed no increase in tumor
growth compared with wild-type littermates (Supplementary
Figure 4). These ﬁndings demonstrate that E2F7 and E2F8 function
as tumor suppressors in the skin when keratinocytes are exposed
to oncogenic stress.
Loss of E2F1 accelerates tumorigenesis in E2F7/8-deﬁcient skin
tumors
As E2F1 is required to induce apoptosis in E2f7Δ/ΔE2f8Δ/Δ
keratinocytes under DNA damaging conditions (Figure 4), we
investigated whether E2F1 contributes to the enhanced tumor-
igenesis observed in E2f7/8-deﬁcient skin. Surprisingly, E2f7Δ/Δ
E2f8Δ/ΔE2f1−/− mice developed signiﬁcantly more and larger
tumors than control and E2f7Δ/ΔE2f8Δ/Δ littermates during two-
stage carcinogenesis (Figures 5a–c). In addition, tumors grew
faster, and reached SSC-2 and SSC-3 stages more often (Figures 5d
and e). Moreover, we found metastatic nodules in adjacent lymph
nodes of E2f7Δ/ΔE2f8Δ/ΔE2f1−/− mice (3 out of 18), which were not
observed in mice of the other genotypes (Figure 5g). Collectively,
these results demonstrate that deletion of E2f1 further aggravates
tumor progression in mice lacking E2F7 and E2F8. Importantly,
deletion of E2f1 alone did not have a discernible effect in DMBA/
TPA-induced skin tumor formation compared with control mice
(Supplementary Figure 5).
Atypical E2Fs and their target genes are upregulated in human
squamous cell carcinomas
Since atypical E2Fs function as transcriptional repressors, we
determined whether increased expression of atypical E2F target
genes was observed in human squamous cell carcinomas. We
analyzed a public microarray data set to compare expression of
atypical E2F target genes in human cutaneous SCC and normal
skin (GSE7553). We initially focused on all genes that showed E2F7
binding in proximal promoter regions by ChIP-sequencing in HeLa
cells, an epithelial cancer cell line.4 From the 737 genes we
previously identiﬁed as E2F7 targets, microarray expression data
were available for 676 transcripts. We found that ~ 50% of these
genes showed signiﬁcantly altered expression in human SCC, most
were upregulated, consistent with the loss of repressor function of
atypical E2Fs (Figure 6a, Supplementary Table S4 up vs 84 down).
As a consequence, normal skin and SCC samples could be
distinguished by unsupervised hierarchical clustering based on
the expression data of these 676 E2F7 target genes. Most of the
255 upregulated E2F7 genes in human SCC are well-known E2F
target genes. Eighty percent of these E2F7 bound and upregu-
lated genes contain at least one consensus E2F motif in their
proximal promoters (Supplementary Figure 6). Gene ontology
showed that DNA metabolism, DNA replication, DNA repair and
related terms were highly overrepresented among the E2F7 target
genes overexpressed in human SCC (Figure 6b, Supplementary
Table S5).
Next, we determined the expression levels of the activator E2Fs
and atypical E2Fs in human SCC samples (Figure 6c). Of the
activator arm of the E2F family, only E2F3 was signiﬁcantly
increased in human SCC. Remarkably, both atypical E2Fs were
upregulated as well in human SCC, despite increased expression
of many of their E2F target genes. As E2F7/8 promoters contain
E2F-binding sites,9 their expression can be induced by activator
E2Fs, presumably to counterbalance the E2F activity in
proliferating cells.
Deregulated E2F7 target gene expression in SCC, despite high
E2F7 and E2F8 transcript levels, raised the question if target genes
were even further upregulated upon deletion of E2F7 and E2F8. To
this end, we selected a panel of some of the most highly
upregulated E2F target genes in human SCC samples (RRM2,
CHEK1 and UHRF1; Figure 6c), and evaluated the transcript levels
of these targets in mouse SCC-1 samples by qPCR. All these E2F
target genes were consistently increased in E2f7Δ/ΔE2f8Δ/Δ SCC-1
tumors compared with control tumors (Figure 6d). Importantly,
triple-knockout SCCs showed a similar increase in the expression
of E2F target genes, showing that additional deletion of E2f1 did
not rescue the increased expression of these E2F targets in mouse
Figure 3. E2F7 and E2F8 inhibit DNA replication in response to DNA damage. (a) Representative immunoﬂuorescence pictures and
quantiﬁcation of γH2Ax staining after 8 h etoposide treatment (10 μM) in keratinocytes. Each plot represents 500–1000 individual cells per
independent keratinocyte line (n= 3). (b) DNA synthesis shown by BrdU incorporation after 8 h etoposide treatment (10 μM) in keratinocytes.
Averages per line were determined by analyzing 500–1000 cells (n= 3 per genotype). (c) Mitotic index of keratinocytes in response to 8 h of
etoposide treatment (10 μM), shown by pH3 staining. A dotted staining was indicative for late G2-phase, and pan-nuclear staining indicates
mitotic (M) cells. Averages per line were determined by analyzing 500–1000 cells (n= 3 per genotype). (d) Mitotic index of keratinocytes in
response to 8 h of etoposide treatment (1 or 5 μM, as indicated), shown by pan-nuclear pH3 staining. (e) Immunoblots showing expression of
indicated proteins in whole cell lysates from keratinocytes of indicated genotypes after 8 h etoposide treatment (10 μM). (f) qPCR analysis of
Cyclin B1 transcripts in keratinocytes with indicated genotypes after 8 h etoposide treatment (10 μM). Data are of 3–5 replicates, derived from
three different lines per genotype. (g) Transcript levels of indicated E2F target genes in keratinocytes after 8 h etoposide treatment (10 μM).
Data are of 3–5 replicates, derived from three different keratinocyte lines. (a–f) *Po0.05 vs control+vehicle; #Po0.05 vs control+etoposide.
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SCC deﬁcient for atypical E2Fs (Figure 6d). These observations
suggest that E2F1 tumor suppressor activities in E2f7Δ/ΔE2f8Δ/Δ
SCCs are most likely not related to regulating E2F target genes
involved in DNA metabolism, replication or repair.
In conclusion, atypical E2F target genes are induced during
human cutaneous SCC, and we show that loss of E2F7 and E2F8
further deregulates expression of these genes in mouse cutaneous
SCC, which associates with enhanced tumorigenesis. These
ﬁndings suggest that atypical E2Fs act as tumor suppressors
through transcriptional repression of deregulated E2F target
genes that drive DNA metabolism and replication in skin cancer.
DISCUSSION
Misregulation of E2F-dependent transcription is a frequent event
in many different cancers and is thought to be a critical driver of
uncontrolled proliferation of cancer cells. However, the functions
and contributions of individual E2F family members in various
types of cancer are complex and poorly understood.1 This is
especially true for the most recently discovered family members,
E2F7 and E2F8. Previous studies in cancer cell lines and human
tumor specimens have yielded conﬂicting results. Some studies
suggested that atypical E2Fs might function as oncogenes, while
other studies indicate that they might acts as tumor suppressors,
suggesting that the roles of E2F7 and E2F8 depend on the tissue
type and the kind of mutation. Also, all of these studies were
performed in cell lines, or by analysis of patient samples.19,28–31
Here we provide the ﬁrst in vivo evidence that synergistic function
of E2F7 and E2F8 are required for tumor suppression in the skin.
We used the two-stage skin carcinogenesis model to demon-
strate that atypical E2Fs function as tumor suppressors. This
carcinogenesis model induces oncogenic stress with activation of
Ras oncogenes and accumulation of other DNA mutations, and
subsequent transformation of cells.32 One defense mechanism
against this type of stress is the activation of a transient or
permanent cell cycle arrest via DNA damage response.33 We show
that E2F7 and E2F8 inhibit DNA replication under DNA damaging
conditions in keratinocytes, suggesting that atypical E2Fs suppress
tumorigenesis by inducing a cell cycle arrest. Two recent papers
show that E2F7 transcription is induced by P53 during DNA
damage.7,8 We found that keratinocytes deleted for E2f7 and E2f8
show a normal induction of P53 and its downstream target gene
P21 in response to DNA damage, suggesting that E2F7 could
indeed act as an important mediator of the P53-dependent cell
cycle arrest. However, it should be noted that the regulation of
atypical E2Fs in response to DNA damage might be more
complex. E2F8 is not a conﬁrmed P53 target,7,8 but its induction
in response to DNA damage has previously been reported in cell
lines.6
A striking observation in our study was that deletion of E2f1
aggravated tumorigenesis in E2f7/8-deﬁcient skin. Similar observa-
tions have been made in other mouse models, where deletion of
E2f1 enhances tumorigenesis in a Myc-transgenic mouse model,
and in mice with skin-speciﬁc deletion of Rb.34,35 Nevertheless, we
and others previously demonstrated that E2F1 counterbalances
the functions of E2F7/8 during various physiological processes
such as embryonic development and liver polyploidization, which
was also reﬂected by opposite regulation of an overlapping set of
target genes.5,18,20 This is clearly different in the current skin
cancer model, as additional deletion of E2f1 did not alter the
expression of multiple E2F target genes in the present study. This
could be related to the fact that other activator E2Fs might
compensate for the loss of E2F1 as it has been previously
observed.36
E2F1 has at least two non-redundant functions that may affect
skin tumorigenesis. First, E2F1 can localize to sites of DNA
damage.24 This localization involves phosphorylation of Ser29 and
interestingly, phosphorylation-dead E2f1S29A knock-in mice are
prone to develop UV-induced skin tumors.37 Deletion of E2F1 in
the DMBA-TPA model had no discernible effect on tumor
progression, suggesting that E2F1 tumor suppression function
might be dependent on the type or dose of DNA damage. When
E2F1 was deleted in combination with atypical E2Fs, the average
amount of γH2Ax phosphorylation in response to DNA damage













































































Figure 4. E2F1 induces apoptosis in keratinocytes during prolonged
DNA damage. (a) FACS analysis of apoptosis in keratinocytes after
24 h of treatment with etoposide (50 μM) or camptothecin (20 μM).
Live cells were labeled with Annexin-V (A5) and DAPI. Cells staining
positive for A5 and negative for DAPI (A5+/DAPI−, red boxes) are
apoptotic. (b) Quantiﬁcation of the A5+/DAPI− populations in the
FACS plots (n= 3 per genotype). *Po0.05 vs control. (c) Represen-
tative TUNEL staining and quantiﬁcation of mouse epidermis, 24 h
after a single application of DMBA. Data are presented as number of
TUNEL-positive cells per mm epidermis (control n= 10; 78Δ/Δ and
78Δ/Δ1−/− n= 12).
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Figure 5. Atypical E2Fs inhibit tumor growth and progression in DMBA/TPA-induced carcinogenesis. (a) Two weeks after a single dermal
application of DMBA (initiation), bi-weekly applications of TPA (promotion) were performed for a period of 15 weeks, as indicated by arrows.
(b) Average number of tumors per mouse, classiﬁed by tumor diameter, during the ﬁrst 12 weeks of TPA treatment (control n= 20; 78Δ/Δ n= 19;
78Δ/Δ1−/− n= 18). *Po0.05 compared with control, #Po0.05 vs 78Δ/Δ, one-way ANOVA on repeated measurements with Bonferroni correction
for multiple testing. (c) Cumulative incidence of large tumors (diameter 48 mm; control n= 20; 78Δ/Δ n= 19; 78Δ/Δ1−/− n= 18). *Po0.001 vs
control, #Po0.001 vs 78Δ/Δ, log-rank, Mantel–Cox test. (d) Average papilloma growth rates (control n= 99; 78Δ/Δ n= 85; 78Δ/Δ1−/− n= 71).
*Po0.05 vs control. (e) Quantiﬁcation of malignant progression by histological classiﬁcation of skin tumors. The following categories were
distinguished: hyperplasia; papilloma; carcinoma in situ; SCC grade 1; grade 2; grade 3. *Po0.001 vs control, chi-square test. (f) Representative
photos of tumor stages quantiﬁed in e. Scale bars indicate 1 mm in low-magniﬁcation pictures and 50 μm in high-magniﬁcation pictures.
(g) Representative photos of lymph-node metastasis observed in 78Δ/Δ1−/− mice. Scale bar indicates 1 mm in low magniﬁcation and 200 μm
in high-magniﬁcation picture.
Atypical E2Fs function as tumor suppressors
I Thurlings et al
835
Oncogene (2017) 829 – 839
might not be required for DNA repair. However, closer inspection
at single cell level revealed that there was a subpopulation of
triple-knockout cells that expressed extremely high levels of
phosphorylated γH2Ax in response to DNA damage, indicating
that inactivation of E2F1 resulted in more DNA damage in a subset
of cells that might be more prone to transformation. Alternatively,
cells with unrepaired DNA might be less cancer-prone, because
they could die due to catastrophic events during mitosis.
Interestingly, we observed that a subpopulation of E2f7/8/1-
deﬁcient keratinocytes displayed reduced DNA damage, indicat-
ing that E2f1 deﬁciency might also promote DNA repair. If this
enhanced DNA repair events are more error-prone it could
increase the chance of oncogenic transformation and could
thereby represent another mechanism for the enhanced tumor-
igenesis phenotype in E2f7/8/1-deﬁcient keratinocytes.
However, another potential mechanism how E2F1 could
function as tumor suppressor in the skin is its ability to induce
apoptosis.38,39 DNA damage leads to multiple post-translational
modiﬁcations of E2F1, resulting in stabilization and increased
binding and transactivation of pro-apoptotic target genes,
including P73, Caspase-3 and Apaf1.25,39,40 Suppression
of apoptosis is a hallmark of cancer and can drive progression
of many cancer types, including squamous cell carcinomas.41,42
We show that inactivation of E2f1 in E2f7/8 deﬁcient keratinocytes
suppresses apoptosis in vitro and in vivo, which is line with
previous in vitro studies.6,19 These ﬁndings suggest that E2F1
functions as a tumor suppressor by inducing apoptosis in E2f7/8-
deﬁcient keratinocytes under stress conditions.
Similar to E2F1, E2F7 has also been shown to localize and bind
to regions of DNA damage.22 In this study, inactivation of E2F7 in
U2OS cells resulted in increased phosphorylation of γ-H2AX after
recovery of camptothecin-induced DNA damage. These ﬁndings
indicate that E2F7 might be required for proper DNA repair and
could represent a potential tumor-suppressor function of atypical
E2Fs. However in our studies, we have not detected any signiﬁcant
differences in phosphorylation of γ-H2AX between wild-type and
E2F/8-deﬁcient murine keratinocyte in response to etoposide. The
reason for this discrepancy is unclear, but might be related to the
different experimental settings, such as choice of DNA damaging
drug, species and cell type.
Our studies demonstrate that combined deletion of E2f7 and
E2f8 in keratinocytes resulted in upregulation of E2F target genes
under DNA-damaging conditions and in mouse skin tumors,
which is consistent with the transcriptional repressor function of
atypical E2Fs,4,10,19 Many of these atypical E2Fs target genes are
involved in the initiation and progression of DNA replication.4
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Figure 6. E2F7-target genes are highly expressed in human SCC and are further increased by the deletion of E2f7 and E2f8. (a) Heatmap
showing expression of E2F7 target genes in human cutaneous SCC and normal skin. (b) PANTHER gene ontology (GO) analysis of the 255
upregulated E2F7 target genes as shown in heatmap. Benjamini-adjusted log P-values were calculated using DAVID.49 (c) Expression of
E2F family members and E2F target genes in human cutaneous SCC, determined by the Riker microarray data48 (normal skin n= 4; SCC n= 11).
(d) Evaluation of transcript levels of E2F target genes in mouse SCC-1 samples (control n= 6; 78Δ/Δ n= 7; 78Δ/Δ1−/− n= 8).
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Importantly, these atypical E2F7/8 target genes were also
upregulated in human squamous cell carcinomas, indicating that
deregulation of E2F7/8 target genes might contribute to skin
tumorigenesis in mice and humans. Evaluation of the COSMIC and
TCGA databases revealed that genetic alterations of E2F7 and
E2F8 are very infrequent, and the chance that both atypical E2Fs
are mutated in the same tumor is extremely small. Therefore,
forcing tumor cells to express high levels of E2F7 and/or E2F8
could be a promising strategy to inhibit E2F activity in tumor cells.
We show that deletion of atypical E2Fs in skin tumors leads
to further deregulation of E2F target genes accompanied with
acceleration of tumorigenesis indicating that atypical E2Fs can
counterbalance deregulated E2F activity to suppress tumorigen-
esis. For that reason, further enhancement of atypical E2Fs activity
to downregulate E2F activity in tumor cells could represent a
successful strategy to mitigate tumorigenesis, for example
through blocking degradation of atypical E2Fs. Further investiga-
tions are required to examine how and when E2Fs are degraded,
but studies from our group and others provide evidence that
atypical E2Fs are degraded by the APC/CCdh1 complex.43,44 These
ﬁndings might open new avenues for therapeutic approaches to
inhibit abundant E2F activity during tumorigenesis. Future studies
are required to investigate how the activity of activator E2Fs and
atypical E2Fs can be optimally manipulated to inhibit tumor
growth for different cancer types.
MATERIALS AND METHODS
Animals
The use of laboratory animals was approved by the Animals Ethics
Committee at Utrecht University and performed according to the
institutional and national guidelines. Conventional and conditional E2f7
and E2f8-knockout mice were generated as described.18 K14-Cre and R26R-
LacZLoxP/LoxP mice were purchased from Jackson Laboratory (Bar Harbor,
ME, USA). Conventional E2f1 knockout mice were provided by M
Greenberg (Duke University Medical Center, USA). All mice were bred in
FVB genetic background for at least ﬁve generations. Genotypic analysis of
mice was performed on DNA from ear-clips by PCR. Primer sequences are
shown in Supplementary Table S1. Animals were allocated to experimental
groups based on their genotype and the analysis of the mice was
performed in randomized and blinded manner.
β-galactosidase staining
Staining on skin and tumor tissues was performed as described
previously.20
Wound healing
Dorsal skin of 6-week-old mice was shaved and 6 mm diameter circular
full-thickness biopsy wounds were induced at the dorsal midline, removing
both epidermis and dermis. The height and width of the wounds was
measured at indicated time points after injury to assess the healing rates of
the wounds. The wound area is described as the percentage relative to the
wound area on day 1 after injury.
Primary keratinocyte isolation
Primary mouse keratinocytes were isolated from E17- to E19-day-old
embryos following previously described protocol45 and cultured in deﬁned
keratinocyte CnT-medium (CELLnTEC, Bern, Switzerland, Advanced Cell
Systems AG, CnT-07). The success rate was deﬁned as the percentage of
successful isolation and subsequent culturing primary murine keratinocyte
cell lines in relation to the total number of isolation attempts per genotype
group. When primary keratinocytes were established and cultured for
more than three passages from the skin of a mouse embryo, this was
counted as a successful isolation.
Cell count
Keratinocytes were plated under low (7000 cells/cm2) or high (177.000
cells/cm2) conﬂuency conditions. Cells growing under low conﬂuency were
counted 8 days after plating. Cells growing under high conﬂuency were
passaged once at 4 days, and counted after 8 days.
Immunoﬂuorescence microscopy
Keratinocytes were cultured on glass coverslips, treated with etoposide
(10 μM) for 8 h and ﬁxed in 4% PFA for 10 min at room temperature. For 5-
bromo-2′-deoxyuridine (BrdU) detection, cells were treated with BrdU
(Sigma, St Louis, MO, USA, B5002) 6 h before ﬁxation. Cells were incubated
with 2 M HCl for 20 min, followed by addition of 0.1 M sodium borate
(Na2B4O7), pH 8.5 for 2 min. Cells were washed with PBS and permeabilized
with 0.2% triton/PBS for 5 min. Immunoﬂuorescence staining was done
by anti-BrdU-FITC for 2 h. Coverslips were mounted on slides using
Fluoroshield mounting medium containing DAPI (Sigma, F6057).
Cells were ﬁxed with 4% PFA/0.1% triton/PBS for 10 min at room
temperature for immunoﬂuorescence staining for γ-H2Ax and pH3.
Cells were blocked with 4% BSA/TBS for 30 min, and incubated for 2 h
with primary antibodies dissolved in 2% BSA/TBS. Cells were washed and
incubated with a secondary antibody conjugated with Alexa-Fluor 488 for
1 h. DAPI was used as nuclear counterstaining. Images were taken using a
Leica TCS SPE-II confocal microscope and analyzed using Fiji software.46
Used antibodies are in Supplementary Table S2.
Western blot analysis
Protein isolation and western blot analysis were performed as previously
described.4 Used antibodies are in Supplementary Table S2. Uncropped
versions of the western blots are shown in Supplementary Figure 7.
qPCR
RNA isolation, cDNA synthesis and qPCR were done as described.20
Gene expression was calculated using a ΔΔCt method adapted for
multiple reference genes correction,47 correcting for b-actin and Gapdh
(mouse tumors) or 18 S ribosomal RNA and Gapdh (keratinocytes). Primer
sequences are included in Supplementary Table S3.
Flow cytometry
Keratinocytes were treated 24 h with etoposide (50 μM) or camptothecin
(20 μM; Sigma C9911), and trypsinized. Annexin V-staining was
performed according to the manufacturer’s protocol (Invitrogen, Carlsbad,
CA, USA, A13202). DAPI (1 ng/ml) was added to the samples to distinguish
between apoptotic and necrotic cells. After ﬁltration of the cell
suspensions on 40 μM cell strainers (Falcon, Amsterdam, The Netherlands),
analysis was performed with a BD FACS Canto II and quantiﬁcations were
done using FlowJo software (TreeStar Inc., Ashland, OR, USA).
Immunohistochemistry
Apoptosis in microscopic mouse skin sections was detected using ApoTag
Plus peroxidase In Situ Apoptosis Kit (TUNEL) (Chemicon, Southampton,
UK, S701) according to manufacturer’s protocol. All slides were counter-
stained with hematoxylin. TUNEL-positive cells per mm epidermis was
determined manually.
Two-stage carcinogenesis protocol
The two-stage carcinogenesis protocol was performed as described
previously.32 For short-term experiments, 25 nmol DMBA/200 μl acetone
was topically applied to skin of 7–9-week-old mice, which were killed
24 h after application. Treated and untreated skin sections were ﬁxed in
4% PFA for histological analysis.
Comparative gene expression analysis
The Gene Expression Omnibus was used to ﬁnd previously published
human cutaneous SCC data sets, and found one Affymetrix HGU113plus2
data set (GSE755348). The raw data (.CEL) ﬁles from the squamous cell
carcinoma (n=11) and normal skin samples (n=4) were analyzed using
Flexarray 1.6.1 software (University of Quebec, Montreal, Canada). Raw
Affymetrix data were normalized using RMA, and tested for signiﬁcant
differences between normal skin and SCC using Empirical Bayes estimation
(Wilson & Wright, New Haven, CT, USA). Using a previously published ChIP-
sequencing analysis,4 we ﬁltered only those genes from the microarray
data that have signiﬁcant E2F7 binding within their promoter regions
(o5 kb from transcription start site). Unsupervised hierarchical clustering
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based on expression of all E2F7 target genes was performed using the
Euclidian distance method. E2F binding motif analysis was performed as
described.4 Heatmaps reﬂecting normalized expression data were
generated using Gene-E (https://www.broadinstitute.org/cancer/soft
ware/GENE-E/). Gene ontology analysis of E2F7 target genes according
to expression changes in human SCC was performed using PANTHER
Biological Pathways tool in DAVID.49
Statistics
Data are presented as mean± s.e.m. unless indicated otherwise. Differ-
ences between groups were compared using one-way analysis of variance
followed by Tukey’s post hoc correction. When multiple groups were not
normally distributed, Kruskal–Wallis tests with Dunn’s post hoc correction
were performed. Analysis was performed using SigmaPlot (Systat Software,
San Jose, CA, USA).
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